# R1 CLINICAL-SAFETY REVIEW - osteoid_osteoma

VERDICT: APPROVE (confidence 90)

goldens changed: no (intended: n/a - KB narrative, no engine/golden output touched)

## 1. SAFETY - PASS
No unsafe, misleading, or absolute claim. The narrative is conservative and correct for a benign,
non-metastasising, self-limiting bone lesion:
- NSAIDs positioned as symptom-directed medical management awaiting spontaneous involution, with
  explicit limits (poorly controlled pain, progressive scoliosis, patient preference) - not
  overstated as curative for all.
- CT-guided thermal/RFA ablation of the nidus as definitive option, surgery reserved for
  neurovascular/spinal-cord/joint-adjacent lesions or failed ablation - matches accepted risk logic.
- Malignant mimics (osteoblastoma, Ewing sarcoma, other primary bone malignancy) and atypical
  features (cortical destruction, soft-tissue mass, rapid growth) trigger reconsideration of
  diagnosis and urgent referral. This is the safety-critical red-flag path and it is present.
No false-negative risk: nothing here would cause harm if followed, and it does not tell a clinician
to withhold work-up of a possible malignancy.

## 2. GROUNDING - PASS
No claim is mis-attributed to DeVita. Every clinical sentence is inline-tagged "(general oncology
standard, not from DeVita's section on this disease)", and the closing line frames DeVita as a
NEGATIVE citation - explicitly stating the 12th ed. does not cover this entity in the supplied text.
Adversarial verdict independently confirmed via grep that "osteoid osteoma"/"nidus"/"Brodie" have
zero DeVita hits and "osteoblastoma" appears only as a differential name-drop. Claims are
uncontroversial WHO-classification / orthopaedic-oncology standard of care. Nothing fabricated or
outdated.

## 3. DOSE-FREE - PASS
No numeric dose. Regex scan (mg, mg/m2, AUC, Gy, mCi, q-schedules) is clean; only digit in the file
is "12th" in the edition citation. Confirmed.

## 4. SCOPE - PASS
Appropriately hedged as decision-support: options framed around patient preference, "discuss two
broad options," referral-heavy, no directive to perform a specific procedure. Not a directive.

## 5. ADVERSARIAL FLAGS - no blocking issue
Adversarial verdict returned CLEAN (not ISSUES); no flagged ungrounded/mis-sourced/scope-creep claim
remains. The task rule ("do not approve a draft that cites DeVita for a claim not in DeVita") is not
triggered - this draft explicitly disclaims DeVita rather than citing it.

## Advisory (non-blocking - do not gate)
- Citation line names "NCCN Guidelines where general staging/referral conventions are used," yet the
  body correctly says there is no staging system for osteoid osteoma. NCCN has no osteoid-osteoma
  content either. Tighten to avoid reading as citation-padding: either drop the NCCN mention or
  substitute a dedicated orthopaedic-oncology / WHO Classification of Tumours source as the real
  attribution. Cosmetic/attribution only, not a safety or grounding defect.
- The FLAG header ("needs manual sourcing") is honest and should remain until a musculoskeletal
  oncology reference is substituted; recommend that swap before final KB publish, but it is not a
  blocker for the management field given the content is uncontroversial standard of care.
